Transforming Growth Factor β Receptor Type I Inhibitor, Galunisertib, Has No Beneficial Effects on Aneurysmal Pathological Changes in Marfan Mice |
Park, Jeong-Ho
(College of Pharmacy, Chung-Ang University)
Kim, Min-Seob (College of Pharmacy, Chung-Ang University) Ham, Seokran (College of Pharmacy, Chung-Ang University) Park, Eon Sub (Department of Pathology, College of Medicine, Chung-Ang University) Kim, Koung Li (College of Pharmacy, Chung-Ang University) Suh, Wonhee (College of Pharmacy, Chung-Ang University) |
1 | Schleifenbaum, J., Kassmann, M., Szijarto, I. A., Hercule, H. C., Tano, J. Y., Weinert, S., Heidenreich, M., Pathan, A. R., Anistan, Y. M., Alenina, N., Rusch, N. J., Bader, M., Jentsch, T. J. and Gollasch, M. (2014) Stretch-activation of angiotensin II type 1a receptors contributes to the myogenic response of mouse mesenteric and renal arteries. Circ. Res. 115, 263-272. DOI |
2 | Serova, M., Tijeras-Raballand, A., Dos Santos, C., Albuquerque, M., Paradis, V., Neuzillet, C., Benhadji, K. A., Raymond, E., Faivre, S. and de Gramont, A. (2015) Effects of signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 6, 21614-21627. DOI |
3 | Wisler, J. W., Harris, E. M., Raisch, M., Mao, L., Kim, J., Rockman, H. A. and Lefkowitz, R. J. (2015) The role of beta-arrestin2-dependent signaling in thoracic aortic aneurysm formation in a murine model of Marfan syndrome. Am. J. Physiol. Heart Circ. Physiol. 309, H1516-H1527. DOI |
4 | Xiong, W., Meisinger, T., Knispel, R., Worth, J. M. and Baxter, B. T. (2012) MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome. Circ. Res. 110, e92-e101. DOI |
5 | Yang, H. H., Kim, J. M., Chum, E., van Breemen, C. and Chung, A. W. (2009) Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome. Br. J. Pharmacol. 158, 1503-1512. DOI |
6 | Zou, Y., Akazawa, H., Qin, Y., Sano, M., Takano, H., Minamino, T., Makita, N., Iwanaga, K., Zhu, W., Kudoh, S., Toko, H., Tamura, K., Kihara, M., Nagai, T., Fukamizu, A., Umemura, S., Iiri, T., Fujita, T. and Komuro, I. (2004) Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol. 6, 499-506. DOI |
7 | Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., Podowski, M., Neptune, E. R., Halushka, M. K., Bedja, D., Gabrielson, K., Rifkin, D. B., Carta, L., Ramirez, F., Huso, D. L. and Dietz, H. C. (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117-121. DOI |
8 | Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., Benhadji, K. A., Slapak, C. A. and Lahn, M. M. (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des. Devel. Ther. 9, 4479-4499. |
9 | Hibender, S., Franken, R., van Roomen, C., Ter Braake, A., van der Made, I., Schermer, E. E., Gunst, Q., van den Hoff, M. J., Lutgens, E., Pinto, Y. M., Groenink, M., Zwinderman, A. H., Mulder, B. J., de Vries, C. J. and de Waard, V. (2016) Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ marfan mouse model. Arterioscler. Thromb. Vasc. Biol. 36, 1618-1626. DOI |
10 | Akhurst, R. J. and Hata, A. (2012) Targeting the TGF signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790-811. DOI |
11 | Dietz, H. C., Cutting, C. R., Pyeritz, R. E., Maslen, C. L., Sakai, L. Y., Corson, G. M., Puffenberger, E. G., Hamosh, A., Nanthakumar, E. J., Curristin, S. M., Stetten, G., Meyers, D. A. and Francomano, C. A. (1991) Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352, 337-339. DOI |
12 | Kim, K. L., Yang, J. H., Song, S. H., Kim, J. Y., Jang, S. Y., Kim, J. M., Kim, J. A., Sung, K. I., Kim, Y. W., Suh, Y. L., Suh, W. and Kim, D. K. (2013) Positive correlation between the dysregulation of transforming growth factor-beta1 and aneurysmal pathological changes in patients with Marfan syndrome. Circ. J. 77, 952-958. DOI |
13 | Holm, T. M., Habashi, J. P., Doyle, J. J., Bedja, D., Chen, Y., van Erp, C., Lindsay, M. E., Kim, D., Schoenhoff, F., Cohn, R. D., Loeys, B. L., Thomas, C. J., Patnaik, S., Marugan, J. J., Judge, D. P. and Dietz, H. C. (2011) Noncanonical TGF signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332, 358-361. DOI |
14 | Judge, D. P. and Dietz, H. C. (2005) Marfan’s syndrome. Lancet 366, 1965-1976. DOI |
15 | Kim, K. L., Choi, C. and Suh, W. (2014) Analysis of disease progression-associated gene expression profile in fibrillin-1 mutant mice: new insight into molecular pathogenesis of marfan syndrome. Biomol. Ther. (Seoul) 22, 143-148. DOI |
16 | Lavoie, P., Robitaille, G., Agharazii, M., Ledbetter, S., Lebel, M. and Lariviere, R. (2005) Neutralization of transforming growth factorbeta attenuates hypertension and prevents renal injury in uremic rats. J. Hypertens. 23, 1895-1903. DOI |
17 | Neptune, E. R., Frischmeyer, P. A., Arking, D. E., Myers, L., Bunton, T. E., Gayraud, B., Ramirez, F., Sakai, L. Y. and Dietz, H. C. (2003) Dysregulation of TGF activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33, 407-411. DOI |
18 | Matt, P., Schoenhoff, F., Habashi, J., Holm, T., Van Erp, C., Loch, D., Carlson, O. D., Griswold, B. F., Fu, Q., De Backer, J., Loeys, B., Huso, D. L., McDonnell, N. B., Van Eyk, J. E. and Dietz, H. C. (2009) Circulating transforming growth factor-beta in Marfan syndrome. Circulation 120, 526-532. DOI |